Ticker

Analyst Price Targets — ASC

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
October 28, 2025 12:52 pmJonathan ChappellEvercore ISI$15.00$12.44TheFly Ardmore Shipping price target raised to $15 from $13 at Evercore ISI
July 30, 2025 7:45 pmEvercore ISI$13.00$10.72StreetInsider Ardmore Shipping Corporation (ASC) PT Raised to $13 at Evercore ISIMember Login
October 23, 2024 5:03 amlonger ton-milesStifel Nicolaus$17.00$16.22TheFly Ardmore Shipping downgraded to Hold from Buy at Stifel
July 24, 2024 7:26 amBenjamin NolanStifel Nicolaus$24.00$21.30TheFly Ardmore Shipping price target raised to $24 from $22 at Stifel
March 25, 2024 6:34 amOmar NoktaJefferies$20.00$16.35Benzinga Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 5% Dividend Yields
November 29, 2022 9:20 amJefferies$17.00$15.20Benzinga Jefferies Maintains Buy on Ardmore Shipping, Raises Price Target to $17
April 22, 2022 6:17 amH.C. Wainwright$8.50$5.51Benzinga HC Wainwright & Co. Maintains Buy on Ardmore Shipping, Raises Price Target to $8.5

Latest News for ASC

Brokerages Set Ardmore Shipping Corporation (NYSE:ASC) Target Price at $13.67

Ardmore Shipping Corporation (NYSE: ASC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to

Defense World • Feb 16, 2026
Ardmore Shipping Corporation Announces Financial Results For The Three and Twelve Months Ended December 31, 2025

HAMILTON, Bermuda, Feb. 12, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and twelve months ended December 31, 2025. Highlights and Recent Activity Reported Adjusted earnings of $11.6 million and net income attributable to common stockholders of $9.3 million for the three months ended December 31, 2025, or $0.28 Adjusted…

PRNewsWire • Feb 12, 2026
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

-   Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. -   I n NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once - daily dosing for 7 days.

PRNewsWire • Feb 10, 2026
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40…

GlobeNewsWire • Feb 2, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for ASC.

No Senate trades found for ASC.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top